Novartis AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma
Completed
- Conditions
- BRAF V600 Mutated-Stage III/IV Melanoma
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 38
- Registration Number
- NCT06557291
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies
Completed
- Conditions
- Clinically Isolated SyndromeRelapsing-remitting Multiple SclerosisSecondary Progressive Multiple SclerosisRelapsing Multiple Sclerosis
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 326
- Registration Number
- NCT06526000
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib
Completed
- Conditions
- Chronic Myeloid Leukemia, Chronic Phase
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 111
- Registration Number
- NCT06516029
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia
Completed
- Conditions
- HypercholesterolemiaAtherosclerotic Cardiovascular Disease
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 95
- Registration Number
- NCT06507852
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study
Completed
- Conditions
- Hormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 121
- Registration Number
- NCT06463626
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 143
- Registration Number
- NCT06459232
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
Completed
- Conditions
- Secondary Progressive Multiple SclerosisRelapsing Multiple SclerosisClinically Isolated SyndromeRelapsing Remitting Multiple Sclerosis
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 113
- Registration Number
- NCT06395909
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients
Completed
- Conditions
- Metastatic Melanoma
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1795
- Registration Number
- NCT06369428
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.
Phase 2
Completed
- Conditions
- Human Influenza
- Interventions
- Biological: Aggripal®
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 126
- Registration Number
- NCT02427750
- Locations
- 🇧🇷
100, Salvador, Bahia, Brazil
Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)
Phase 1
Completed
- Conditions
- Pertussis
- Interventions
- Biological: aP boosterBiological: TdaP boosterBiological: Licensed TdaP booster (Boostrix®)
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 315
- Registration Number
- NCT02382913
- Locations
- 🇧🇪
Site 02, Center for Vaccinology (CEVAC), Ghent University Hospital, Ghent, Belgium
© Copyright 2025. All Rights Reserved by MedPath